Opthea's Phase 3 Trials for Wet AMD Treatment with Sozinibercept Complete Participant Enrollment
Tuesday, 28 May 2024, 08:44
Opthea's Phase 3 Clinical Program Progresses:
Opthea has achieved a key milestone by completing the enrollment phase of its pivotal Phase 3 trials with Sozinibercept for the treatment of Wet AMD.
Significance for Wet AMD Treatment:
This advancement represents a critical step towards potentially introducing an innovative treatment option for individuals with Wet AMD, a prevalent eye condition.
Opthea's Phase 3 trials with Sozinibercept hold promise for addressing the unmet medical needs of patients suffering from Wet AMD.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.